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Abstract. Prognosis of pancreatic cancer is poor, thus 
the development of novel therapeutic drugs is necessary. 
During preclinical studies, appropriate models are essen-
tial for evaluating drug efficacy. The present study sought 
to determine the ideal pancreatic cancer mouse model for 
reliable preclinical testing. Such a model could accurately 
reflect human pancreatic cancer phenotypes and predict 
future clinical trial results. Systemic pathology analysis 
was performed in an orthotopic transplantation model to 
prepare model mice for use in preclinical studies, mimicking 
the progress of human pancreatic cancer. The location and 
the timing of inoculated cancer cell metastases, pathogen-
esis and cause of fatality were analyzed. Furthermore, the 
efficacy of gemcitabine, a key pancreatic cancer drug, was 
evaluated in this model where liver metastasis and perito-
neal dissemination occur. Results indicated that the SUIT-2 
orthotopic pancreatic cancer model was similar to the pheno-
typic sequential progression of human pancreatic cancer, 
with extra-pancreatic invasion, intra-peritoneal dissemina-
tion and other hematogenous organ metastases. Notably, 
survival was prolonged by administering gemcitabine to 
mice with metastasized pancreatic cancer. Furthermore, 
the detailed effects of gemcitabine on the primary tumor 
and metastatic tumor lesions were pathologically evaluated 
in mice. The present study indicated the model accurately 
depicted pancreatic cancer development and metastasis. 
Furthermore, the detailed effects of pancreatic cancer drugs 
on the primary tumor and on metastatic tumor lesions. We 
present this model as a potential new standard for new drug 
development in pancreatic cancer.
Introduction
Patients with pancreatic cancer increase in number every 
year. Pancreatic cancer is typically associated with extremely 
poor prognosis. Even with advanced imaging technology and 
diagnosis, many patients are diagnosed at a stage when the 
cancer is unresectable. Even if resected, most will eventually 
metastasize to locations such as the liver or peritoneum (1-3). 
Improvements in chemotherapy are necessary to improve 
the prognosis of pancreatic cancer patients (4). Gemcitabine 
was approved in the United States in 1996 and is a key 
drug for patients with pancreatic cancer (5). In recent years, 
gemcitabine has been administered with nab-paclitaxel. 
Although the survival rate is improved, the prognosis of 
patients with pancreatic cancer remains grim. In vivo animal 
models are important for facilitating the rapid development of 
effective drugs. These models imitate metastatic patterns and 
allow for close examination of the therapeutic effects of new 
medications.
Therefore, several mouse models are used, including 
orothotopically, heterotopically, syngenic, xenografted (6); 
patient-derived tumor xenografted or genetically engineered 
cancer models (7,8). These models have varied advantages 
pertaining to ease, cost, reproducibility, etc. Generally, 
preclinical drug development examines the effects of the 
subcutaneous implantation model on tumor regression. 
Mia-pa-ca-2, Capan-1, and BX-PC-3 are used as models for 
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pancreatic cancer; however, only BX-PC-3 is used as a model 
for gemcitabine resistance in pancreatic cancer. Our labora-
tory has not confirmed distant metastasis in models involving 
subcutaneous implantation of Capan-1 or SUIT-2 cell lines. 
Therefore, mice that are subcutaneously transplanted with 
these cells cannot be used to assess drug anti-tumor effects 
or metastases. Tumor regression effects alone are insufficient 
for evaluating survival extension and the curability of cancer. 
There is a need to evaluate drugs in multiple ways, deter-
mining if the drug acts on pancreatic tumors, if it suppresses 
metastases, and if it can improve secondary pathologies.
Among these promising models, we expect orthotopic 
xenografted pancreatic cancer models to be preferable because 
the model can evaluate the drug effects on human pancreatic 
cancer cells and imitate the natural metastatic cascades with 
high reproducibility and convenience and without special 
gene engineering technologies or ethical issues related to 
the use of clinical pancreatic cancer specimens. Previous 
studies affirm the usefulness of orthotopic xenografted 
pancreatic cancer model mice in these studies (9-13). There 
are several pancreatic cancer cell lines, and all cell lines do 
not metastasize from orthotopically xenografted pancreas, 
as in the typical course of human pancreatic cancer (14,15). 
In addition, few studies have examined the cell lines suitable 
for evaluating drug efficacy when xenografted cells spread 
from the primary pancreas to the extra-pancreas and distant 
organs. We also do not know when target drugs should be 
started in experimental animal models during preclinical 
testing. Effective drug development requires that we address 
these experimental problems and examine the systemic 
pathological, and therapeutic, effects.
The purpose of this study was to establish an ideal 
pancreatic cancer mouse model for reliable preclinical 
testing. Such a model will accurately reflect human pancre-
atic cancer phenotypes and estimate the results of future 
clinical trials. We focused on the orthotopic pancreatic cancer 
mouse model using the SUIT-2 cell line because this model 
has characteristics similar to the progression phenotypes 
of human pancreatic cancer, with extra-pancreatic invasion, 
intra-peritoneal dissemination, and hematogenous metastases 
to other organs. First, we examined the spread of inoculated 
SUIT-2 cells from primary pancreatic tumors by monitoring 
the systemic and pathological findings. Subsequently, using 
the model mice imitating Stage IV human pancreatic cancer, 
we evaluated the prognostic metastatic inhibition effects 
of gemcitabine treatment, which was started on day 7 and 
day 14 after SUIT-2 inoculation. We sought to determine if 
our focused-SUIT-2 pancreatic cancer model could portray 
the effects of gemcitabine treatment against typical human 
metastatic pancreatic cancer cells.
Materials and methods
Cell cultures and animals. Human pancreatic cancer cell lines 
Capan-1 and SUIT-2 were provided by American Type Culture 
Collection and the Japanese Cancer Research Resources Bank 
(Tokyo, Japan). The cells were cultured in DMEM (Gibco; 
Thermo Fisher Scientific, Inc., Tokyo, Japan) and RPMI‑1640 
(Gibco; Thermo Fisher Scientific, Inc.) supplemented with 
streptomycin (100 mg/ml), penicillin (100 U/ml) (Pen strep; 
Gibco; Thermo Fisher Scientific, Inc.), and 10% fetal bovine 
serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.) in a 
humidified incubator with 5% CO2 at 37˚C.
We purchased 5-week-old female BALBc nu/nu mice from 
Japan SLC (Hamamatsu, Japan). These animals were trans-
ferred to a temperature‑(20‑26˚C) and humidity‑controlled 
(40‑60% relative humidity) room with a 12‑h light/12‑h dark 
cycle during the experimental period. All animal experiments 
were approved by the FUJIFILM Animal Experimentation 
Committee.
Orthotopic implantation. The cells were treated with 
trypsin/EDTA (Gibco; Thermo Fisher Scientific, Inc.) and 
washed with FBS-added and serum-free media twice. Cell 
suspensions of 1x106 cells/0.01 ml were injected into the 
pancreatic tail of mice under anesthesia (isoflurane) (Pfizer, 
Tokyo, Japan). A cotton swab was held over the injection site 
for 1 min to prevent leakage of intrapancreatic tumor cells. 
We measured survival times until death or moribundity (e.g., 
marked decrease in body weight, hypothermia, or other condi-
tions requiring euthanasia).
We orthotopically transplanted Capan-1 and SUIT-2 lines 
(1x106 cells) into mice (Capan-1 n=8, SUIT-2 n=8) and plotted 
the Kaplan-Meier survival curve 72 days after transplantation. 
The mice were sacrificed and examined for tumor spreading 
through the use of macroscopic and microscopic observations 
by hematoxylin and eosin (H&E) staining.
To evaluate the time course of metastatic cascades in the 
orthotopic SUIT-2 model, we made 23 SUIT-2 (1x106 cells) 
model mice and pathologically examined tumor spreading in 
each pancreas, spleen surface, peritoneum, liver, and lung on 
days 3, 7, and 14 after inoculation. H&E sections of the heart, 
lung, trachea, submandibular gland, aorta, liver, kidney, spleen, 
pancreas, adrenal gland, peritoneal cavity, bladder, stomach, 
duodenum, jejunum, ileum, colon, rectum, female genital organs, 
sternum, lymphatic tissues, and abdominal wall were examined.
Evaluation of gemcitabine effects using the orthotopic 
SUIT‑2 pancreatic cancer model. Overall, 40 BALBc nu/nu 
mice were orthotopically inoculated with 1x106 SUIT-2 cells 
(day 0). The mice were randomly divided into three groups: 
the vehicle group (n=20), gemcitabine day 7 group (n=10, 
weekly intravenous injection started 7 days after inoculation; 
240 mg/kg/week, weekly) (Teva Pharmaceutical Industries 
Netanya, Israel), and gemcitabine day 14 group (n=10, weekly 
intravenous injection was started 14 days after inoculation; 
240 mg/kg/week, weekly).
For weekly treatment, 240 mg/kg is reported to be the 
maximal tolerated dose of gemcitabine in mice (16). We 
plotted Kaplan-Meier survival curves 100 days after transplan-
tation for each group. This treatment was performed until the 
final observation week excluding death or moribundity. Tumor 
spreading was evaluated as mentioned above.
H&E stains. Organs and tissues were fixed in 10% neutral 
buffered formalin (Wako Pure Chemical Industries, Ltd., 
Osaka, Japan) and embedded in paraffin (Sakura Finetek Japan 
Co., Ltd., Tokyo, Japan), and 2-µm sections were prepared. 
The sections were stained with H&E (Hematoxylin 3G, 
Sakura Finetek Japan Co., Ltd.; Eosin, Wako Pure Chemical 
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Industries, Ltd.) using standard procedures (Hematoxylin, 
1 min and Eosin, 1 min). Snapshots of histology were taken 
using Olympus BX51 microscope. Images were generated 
using an attached Olympus DP70 camera and the cellSens 
software (Olympus Corporation, Tokyo, Japan).
Statistical analysis. Overall survival was measured from 
the day of SUIT-2 injection and plotted according to the 
Kaplan-Meier method; a log-rank test was used for comparison. 
P<0.05 was considered to indicate a statistically significant 
difference. All statistical analyses were performed using the 
GraphPad Prism5 software package (GraphPad Software, Inc., 
La Jolla, CA, USA).
Results
The orthotopic SUIT‑2 xenografted mouse model resembled the 
spread of typical human pancreatic cancer compared to the 
Capan‑1 mouse model. Among several human pancreatic cell 
lines, we selected Capan-1 and SUIT-2 cells for our orthotopic 
pancreatic cancer mouse model because these cells are trans-
plantable into the mice, and transplanted tumor pathology was 
relatively similar to that of human pancreatic cancer tissues, 
with ductal components and cancer stromal components or poor 
differentiation. Capan-1 and SUIT-2 cells were transplanted 
orthotopically and observed. Capan-1-transplanted mice (n=8) 
had no remarkable abnormal findings, including body weight loss, 
jaundice, or abdominal ascites during the observation period.
Tumor progression in two orthotopic transplantation 
mouse models of pancreatic cancer were evaluated (Fig. 1). On 
dissection on day 72 after inoculation, pancreatic cancer nodules 
were observed in all mice (Fig. 1A). Transplanted Capan-1 
cells were observed in all pancreatic tumors (Fig. 2); however, 
the rate of metastasis was low (50%). SUIT‑2‑transplanted 
mice (n=8) began to die or became moribund from day 20 
after transplantation. Tumor nodules were scattered over the 
pancreas to the spleen, mesenterium, and retroperitoneum on 
necropsy (Fig. 1B). We plotted Kaplan-Meier survival curves 
for Capan-1- and SUIT-2-inoculated mice. The median survival 
of SUIT-2-transplanted mice was 46.5 days. This model led to 
premature death (Fig. 1C). Capan-1-transplanted mice experi-
enced superior prognoses than the SUIT-2-transplanted mice.
To clarify the SUIT-2 spread and the causes of death, dead 
or moribund mice were subjected to macroscopic and patho-
logical observation (Fig. 3). Many mice had carcinomatous 
ascites with bleeding. In some mice, the ascites were more 
than 10 ml (Fig. 3A, left). Jaundiced mice appeared to have 
yellow-colored skin, noses, and limbs (Fig. 3A, right). Most 
mice had single SUIT-2 nodules in the pancreas, with adhe-
sion to surrounding organs such as the spleen and the stomach. 
SUIT-2 cells appeared as white spots and were spread 
throughout the whole body, including the mesenterium, liver, 
and lung (Fig. 3B). Some mice had intestinal dilation due to 
peritoneal dissemination, lymph node metastasis, and pleural 
effusion (data not shown). SUIT-2 tumors in the pancreas 
(moderate to poorly differentiated), atrophy of pancreatic 
acinar cells, mesenteric tumors, hepatic metastases, and lung 
metastases were observed using microscopic observations of 
the SUIT-2 model mice (Fig. 3C). Jaundiced mice displayed 
bile duct dilation (Fig. 3C). Tumor cells (Fig. 4A) were observed 
Figure 1. Tumor progression in two orthotopic transplantation mouse models of pancreatic cancer. (A) The image shows the appearance of orthotopic xeno-
grafted Capan-1 cells in the pancreas and other abdominal organs 72 days after inoculation. (B) The image shows the appearance of orthotopic xenografted 
SUIT-2 cells spreading in the abdominal cavity 72 days after inoculation. (C) The survival rate of the Capan-1 and SUIT-2 models without treatment. Eight 
mice were used in each group.
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in the blood vessels of the lung, and lymph node metastases to 
the mediastinum were also observed by pathological examina-
tion of the whole body (Fig. 4B and C).
SUIT‑2 spread from the pancreas to the extra‑pancreatic 
tissues, including distant organs, in sacrificed mice. To 
investigate cancer spread following transplantation, 23 mice 
were sacrificed on days 3, 7 and 14 after transplantation. 
Representative examples are shown in Fig. 5. The microscopic 
findings and metastatic rates are summarized in Table I. At 
sacrifice 3 days after inoculation, we observed pancreatic 
nodules, covered with a transparent membrane. Microscopic 
examination showed nodule tumor cell formation, covered by 
a membrane. Tumor cells were not observed in other organs.
At sacrifice, 7 days after inoculation, white nodular areas 
were observed on the surfaces of the stomach, spleen, and 
peritoneum, surrounding the transplanted pancreas. Pancreatic 
tumors invaded the pancreatic acinar cells (70%), with spleen 
capsule surface thickening and cancer cell seeding. Cancer 
cells were observed in the mesenterium but not in other organs. 
At this time, we observed 40% peritoneal dissemination. At 
sacrifice on day 14 after inoculation, a large nodule from the 
inoculated pancreas invaded the surrounding tissues, and we 
observed white tumor spots on the surfaces of the spleen and 
stomach. Microscopically, tumor cells disseminated throughout 
the abdominal cavity over the pancreatic serosa. Tumor cells 
were seeded in the capsule of the spleen, as on day 7. Peritoneal 
dissemination was 60% at this time. Many tumor nodules were 
observed in the mesenterium, with 40% liver metastases. Lung 
metastases were not observed on any specimens; however, 
tumor cells in the blood vessels of the lung and mesenteric 
lymph vessels (30%) were noted (data not shown).
Figure 2. Macroscopic and microscopic Capan‑1 tumors in planned‑sacrificed model mice. These images show the appearance of orthotopic xenografted 
Capan‑1 cells of the pancreas 72 days after inoculation. Capan‑1 cells were not present in other organs. (Magnification: pancreas, liver and lung, x40; spleen, 
x100; mesenterium, x50).
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Efficacy of gemcitabine using an orthotopic pancreatic cancer 
model. Survival tests were performed on gemcitabine, a standard 
treatment for pancreatic cancer. Weekly gemcitabine treatment 
occurred on day 7 and day 14 after cell transplantation. A 
survival-prolonging effect was observed in the groups receiving 
gemcitabine as compared with that in the group receiving the 
vehicle (Gemcitabine day 7; P=0.0017) (Gemcitabine day 14: 
P=0.0135; Fig. 6). Median survivals were 46 days for the vehicle 
group, 91.5 days for the gemcitabine day 7 group, and 81.5 days 
for the gemcitabine day 14 group. Mice who died during the test 
in both the vehicle group and gemcitabine-administered groups 
were dissected and examined.
All mice displayed a wide range of metastatic cancer cells 
(data not shown). Surviving mice treated with gemcitabine 
were dissected on day 100 (Table II). Comparing the day 7 
treatment group with the day 14 treatment group, earlier treat-
ment was slightly inhibitory to both liver and lung metastases 
(day 7: 67%, and day 14: 100%). In both groups, pancreatic 
tumor invasion, peritoneal dissemination, liver metastases, 
and lung metastases increased on dissection (day 100), in spite 
of surviving mice.
Discussion
The SUIT-2 orthotopic pancreatic cancer model was similar 
to the phenotypic progression of human pancreatic cancer, 
with extra-pancreatic invasion, intra-peritoneal dissemination, 
and other hematogenous organ metastases, compared to the 
Capan-1 model.
Pathology results clarified when these metastatic lesions 
spread from primary pancreatic tumors. The prognostic effi-
cacy of gemcitabine treatment against metastatic pancreatic 
cancer lesions, similar to Stage IV human pancreatic cancer, 
was also evaluable using this model. Moreover, necropsy on 
the final observation day showed the suppression of distant 
metastases in the day 7 treatment group compared to that in the 
day 14 group. However, all mice displayed xenografted tumors 
in spite of the continuous gemcitabine treatment, similar to 
typical human pancreatic cancer.
The SUIT-2 orthotopic pancreatic cancer mouse model has 
been used in other studies for evaluating promising new anti-
cancer agents (14,17-20). Cherubini et al (17) used the model 
to evaluate target drug survival effects. Saimura et al (19)
Figure 3. Macroscopic and microscopic SUIT-2 tumors in the model mice with end-stage pancreatic cancer. (A) Left panel shows the bloody ascites of a 
representative model mouse. Right panel shows the severe body weight and jaundice of a representative model mouse. (B) Macroscopic appearance of SUIT-2 
tumors in the abdominal cavity and thoracic cavity of the model mice. (C) Microscopic findings of SUIT‑2 tumors in the pancreas, mesenterium, liver, and 
lung of the model mice. (Magnification: pancreas and mesenterium, x20; liver, x200 and x40; lung, x100).
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Figure 5. Macroscopic and microscopic SUIT‑2 tumors in planned‑sacrificed model mice. Upper panel: Macroscopic and microscopic SUIT‑2 tumors in 
the pancreas on day 3 after inoculation (magnification, x20). Middle panel: Macroscopic and microscopic SUIT‑2 tumors in the pancreas and mesenterium 
surrounding the pancreas on day 7 after inoculation (magnification: left, x40x; center, x100; right, x40). Lower panel: Macroscopic and microscopic SUIT‑2 
tumors in the pancreas, mesenterium surrounding pancreas, and liver metastasis on day 14 after inoculation (magnification: left and center left, x100; center 
right, x40; right, x500).
Figure 4. Microscopic SUIT‑2 tumors in model mice with end‑stage pancreatic cancer. (A) Tumor cells in the vascular of the lung (magnification, x200). 
(B) Low power view of lymph node metastasis in the mediastinal cavity (magnification, x40). (C) High power view of lymph node metastasis in the mediastinal 
cavity (magnification, x200).
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evaluated the tumor reduction effects by measuring tumor 
weight in a mouse model. SUIT-2 is reported not only in an 
orthotopic but also in a subcutaneous model, a peritoneal 
dissemination model, and a lung metastasis model. Previous 
studies evaluated the anti-tumor effects in a subcutaneous 
implantation model, drug effects on peritoneal dissemination 
in a dissemination model, and anti-tumor effects in a lung 
metastasis model (21,22). In this study, we used 30-G thin 
needles and 10 µl of cell suspension for orthotopical injec-
tion into the pancreas to prevent these cells from leaking into 
the abdominal cavity after inoculation. As shown in Table I, 
spreading of the macroscopic tumors into the abdominal 
cavity was not observed on day 3, which is similar to early 
human pancreatic cancer. We closed the pancreatic puncture 
holes by pressing the punctured tissue using cotton swabs for 
1 min. This process may be effective for reproducing early 
pancreatic cancer in an orthotopic mouse model. On the 
other hand, some model mice had the SUIT-2 spreading in 
the extra-pancreatic area, including pancreatic surface and 
abdominal cavity, on day 7 despite our procedures using 
cotton swab. It is suggested that small number of SUIT-2 cells 
are leaked into the extra-pancreatic areas in a part of mice. To 
exclude this possibility, it may be effective to use Matrigel for 
cell suspension and to press the puncture holes using swab for 
more long interval.
The orthotopic mouse model can be used to mimic the 
natural course of human pancreatic cancer metastases. 
However, few researchers have reported on the spreading 
patterns of systemic pancreatic cancer, including invasion, 
peritoneal dissemination around the pancreas, and distant 
metastases. Our model indicated that orthotopically-injected 
SUIT-2 cells sequentially spread from the pancreas to the 
peritoneum, diaphragm, liver, and lungs, similar to human 
pancreatic cancer. We validated this model's ability to mimic 
the terminal stage of pancreatic cancer with hemorrhagic 
ascites, tumor cell metastases, liver failure with jaundice, 
intussusception, and pleural effusion. This experimental 
mouse model was similar to human pancreatic cancers.
We sought to identify the best mouse model for predicting 
the effects of anticancer drugs in humans. Many mouse 
models may not reflect human clinical trial results. For 
instance, ganitumab, aflibercept, and exatecan reportedly 
induce strong anticancer effects without severe side effects in 
preclinical mouse models. However, the agents could not show 
the similar effect in human cancer patients during clinical 
trials (11,23,24). Our model accurately mimics the action of 
gemcitabine in human pancreatic cancers. This mouse model 
can reproduce the anticancer effects from a single gemcitabine 
treatment, including survival prolongation, because all mice 
that survived to day 100 had cancer and displayed limited 
anticancer effects, similar to the gemcitabine effects in human 
Table I. Establishment of microscopic SUIT-2 tumors in the orthotopic pancreatic cancer mouse model according to the 
observation time.
Microscopic findings Day 3 (n=3), (%) Day 7 (n=10), (%) Day 14 (n=10), (%)
Xenografted SUIT-2 (Pancreas) 3/3 (100) 10/10 (100) 10/10 (100)
Extracapsular invasion (Pancreas) 0/3 (0) 7/10 (70) 10/10 (100)
Peritonal dissemination 0/3 (0) 4/10 (40) 6/10 (60)
Liver metastasis 0/3 (0) 0/10 (0) 4/10 (40)
Lung metastasis 0/3 (0) 0/10 (0) 0/10 (0)
Table II. Macroscopic and microscopic SUIT-2 tumors in 
survival mice on the last observation day according to the 
starting date of gemcitabine administration.
Pathological Day 7 Day 14
Characteristics (n=3), (%) (n=3), (%)
Macroscopic findings
(tumorous lesion)
  Pancreas, nodule 3/3 (100) 3/3 (100)
  Spleen surface, white spot 2/3 (67) 2/3 (67)
  Mesenterium, white nodule 3/3 (100) 3/3 (100)
  Kidney surface, white nodule 3/3 (100) 3/3 (100)
  Liver white spot 2/3 ( 67) 3/3 (100)
Microscopic findings
  Xenografted SUIT-2 (Pancreas) 3/3 (100) 3/3 (100)
  Extracapsular invasion (Pancreas) 3/3 (100) 3/3 (100)
  Peritonal dissemination 3/3 (100) 3/3 (100)
  Liver metastasis 2/3 (67) 3/3 (100)
  Lung metastasis 2/3 (67) 3/3 (100)
Figure 6. Kaplan-Meier survival plots in the orthotopic SUIT-2-xenografted 
mouse model according to the starting date of gemcitabine administration. 
Vehicle mice group (n=20) had significantly lower overall survival than 
the gemcitabine day 7 group (n=10) and gemcitabine day 14 group (n=10). 
Vehicle vs. gemcitabine day 7 (**P=0.0017). Vehicle vs. gemcitabine day 14 
(*P=0.0135). Gemcitabine day 7 vs. Gemcitabine day 14 (P=0.5359).
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patients with pancreatic cancer. If new investigational agents 
can cure pancreatic SUIT-2 cells in this mouse model, the agent 
may be useful for treating human pancreatic cancer. In other 
words, using this model, it may be possible to predict drug 
effects within clinical trial contexts, contributing to efficient 
drug development.
We believe that our mouse model correctly reflects the drug 
efficacy of gemcitabine alone therapy in the clinic because the 
monotherapy could not eradicate SUIT-2 cells spreading to the 
whole body. In future, we want to examine the drug efficacy 
of gemcitabine combined therapy using our model because the 
combined therapy with gemcitabine and nab-paclitaxel has 
often been used as a standard chemo-regimen for advanced 
pancreatic patients.
In this model, metastases form throughout the whole body, 
and cancer death results from causes such as liver failure and 
peritoneal dissemination. This model may not be suitable for 
evaluating drug effects against conditions such as liver metas-
tases. Previous studies describe the peritoneal dissemination 
model by intra-peritoneal injection, the liver metastasis model 
by splenic injection or direct liver injection, and the lung 
metastasis model by tail vein injection for preclinical studies 
of pancreatic cancer (25). Such models can evaluate drug 
effects on peritoneal dissemination, liver metastases, and lung 
metastases. After evaluating the effects of survival prolonga-
tion and organ‑specific anti‑tumor effects, using our orthotopic 
mouse model, it might be better to use the abovementioned 
specific metastasis mouse model to understand the therapeutic 
characteristics of the target drugs against organ metastases. 
Moreover, our model has another limitation: our nude mice 
have activity of macrophases and natural killer cells to prevent 
the cancer spreading. In future, we hope to establish the 
orthotopic pancreatic cancer model using specific mice with 
humanized immunoreactivity (26,27) and to investigate the 
metastatic cascades and the therapeutic efficacy of new drug 
candidates using our model.
In conclusion, there are prior reports of the SUIT-2 ortho-
topic pancreatic cancer mouse model for evaluating tumor 
volume or survival time. We clarified the process and timing 
of pancreatic cancer progression in this mouse model, similar 
to that observed in typical human pancreatic cancer patients. 
Through this model, researchers can validate the prognostic 
and therapeutic efficacy of gemcitabine as a key drug for 
treating human pancreatic cancer. Future investigations may 
further affirm the use of this model as a standard model for 
drug development.
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